---
trial_id: 729
discovery_date: 2022-04-24 16:23:21.890463
date: 2022-04-24 16:23:21.890463
title: "A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (AubagioÂ®) in participants with relapsing forms of multiple sclerosis"
summary: |
  <p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT">IT</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO">RO</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000637-41'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2020-000637-41<br />Sponsor Protocol Number: EFC16033<br />Sponsor Name: Genzyme Corporation<br />Start Date: 2020-07-31<br />Medical condition: Relapsing Multiple Sclerosis <br />Disease: <br />Version: 21.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10080700<br />Term: Relapsing multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DE">DE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/BG">BG</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/CZ">CZ</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/FI">FI</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/AT">AT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/LT">LT</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/PL">PL</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/IT">IT</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000637-41/RO">RO</a> (Ongoing)</p>